COVID-19's impact on bioanalytical labs.Bioanalysis. 2021 Aug; 13(15):1169-1171.B
Abstract
Tweetable abstract One year later, the impact of the COVID-19 pandemic on business practices, supply chains, timelines and analytical needs for COVID-19 clinical trials have been felt across the bioanalytical community, as therapeutics may now require SARS-CoV-2 antigen and serological testing.
Links
Pub Type(s)
Editorial
Language
eng
PubMed ID
34374298
Citation
Lavelle, Amy, and Janine Micheli. "COVID-19's Impact On Bioanalytical Labs." Bioanalysis, vol. 13, no. 15, 2021, pp. 1169-1171.
Lavelle A, Micheli J. COVID-19's impact on bioanalytical labs. Bioanalysis. 2021;13(15):1169-1171.
Lavelle, A., & Micheli, J. (2021). COVID-19's impact on bioanalytical labs. Bioanalysis, 13(15), 1169-1171. https://doi.org/10.4155/bio-2021-0103
Lavelle A, Micheli J. COVID-19's Impact On Bioanalytical Labs. Bioanalysis. 2021;13(15):1169-1171. PubMed PMID: 34374298.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - COVID-19's impact on bioanalytical labs.
AU - Lavelle,Amy,
AU - Micheli,Janine,
Y1 - 2021/08/10/
PY - 2021/8/11/pubmed
PY - 2021/8/24/medline
PY - 2021/8/10/entrez
KW - COVID-19
KW - NAAT
KW - SARS-CoV-2 antigen
KW - bioanalysis
KW - clinical trials
KW - serology
SP - 1169
EP - 1171
JF - Bioanalysis
JO - Bioanalysis
VL - 13
IS - 15
N2 - Tweetable abstract One year later, the impact of the COVID-19 pandemic on business practices, supply chains, timelines and analytical needs for COVID-19 clinical trials have been felt across the bioanalytical community, as therapeutics may now require SARS-CoV-2 antigen and serological testing.
SN - 1757-6199
UR - https://www.unboundmedicine.com/medline/citation/34374298/COVID_19's_impact_on_bioanalytical_labs_
DB - PRIME
DP - Unbound Medicine
ER -
Try the Free App:
